Clinical lung cancer
A Comprehensive Analysis of HER2 status Heterogeneity Using Matched Samples among Potential Beneficiaries of Trastuzumab Deruxtecan Therapy in Non-Small Cell Lung Cancer.
Haiyue Wang, Wei Sun, Chenglong Wang, Xin Yang, Kaiwen Chi, Xinying Liu, Xiaozheng Huang, Lixin Zhou, Dongmei Lin
Published: 202510.1016/j.cllc.2025.11.015
Abstract
BACKGROUND: HER2 overexpression is defined as immunohistochemistry (IHC) 2+/3+, and trastuzumab deruxtecan (T-DXd) is approved for treating unresectable or metastatic solid tumors with HER2 3+. HER2 spatiotemporal heterogeneity is crucial for identif…
Preview only. Read the full abstract at the source